Table 1 Correlation between BTNL9 expression and clinical characteristics in patients with thyroid cancer

Age, n (%)

≤ 45

118 (23.5%)

118 (23.5%)

> 45

133 (26.5%)

133 (26.5%)

Gender, n (%)

Female

186 (37.1%)

181 (36.1%)

Male

65 (12.9%)

70 (13.9%)

Race, n (%)

Asian

26 (6.3%)

25 (6.1%)

Black or African American

18 (4.4%)

9 (2.2%)

White

174 (42.4%)

158 (38.5%)

T stage, n (%)

T1

62 (12.4%)

81 (16.2%)

T2

67 (13.4%)

97 (19.4%)

T3

102 (20.4%)

68 (13.6%)

T4

20 (4%)

3 (0.6%)

N stage, n (%)

N0

96 (21.2%)

133 (29.4%)

N1

134 (29.6%)

89 (19.7%)

M stage, n (%)

M0

149 (51.2%)

133 (45.7%)

M1

7 (2.4%)

2 (0.7%)

Pathologic stage, n (%)

Stage I

132 (26.4%)

149 (29.8%)

Stage II

12 (2.4%)

40 (8%)

Stage III

70 (14%)

42 (8.4%)

Stage IV

36 (7.2%)

19 (3.8%)

Histological type, n (%)

Classical

198 (39.4%)

158 (31.5%)

Follicular

20 (4%)

81 (16.1%)

Other

2 (0.4%)

7 (1.4%)

Tall Cell

31 (6.2%)

5 (1%)

Residual tumor, n (%)

R0

185 (42%)

199 (45.2%)

R1

35 (8%)

17 (3.9%)

R2

3 (0.7%)

1 (0.2%)

Extrathyroidal extension, n (%)

No

138 (28.5%)

193 (39.9%)

Yes

105 (21.7%)

48 (9.9%)

Primary neoplasm focus type, n (%)

Multifocal

100 (20.3%)

126 (25.6%)

Unifocal

148 (30.1%)

118 (24%)

Neoplasm location, n (%)

Bilateral

40 (8.1%)

46 (9.3%)

Isthmus

12 (2.4%)

10 (2%)

Left lobe

85 (17.1%)

90 (18.1%)

Right lobe

109 (22%)

104 (21%)

Thyroid gland disorder history, n (%)

Lymphocytic Thyroiditis

37 (8.3%)

34 (7.7%)

Nodular Hyperplasia

23 (5.2%)

45 (10.1%)

Normal

149 (33.6%)

131 (29.5%)

Other, specify

12 (2.7%)

13 (2.9%)

Living status, n (%)

Alive

242 (48.2%)

244 (48.6%)

Dead

9 (1.8%)

7 (1.4%)

Age, median (IQR)

46 (35, 58)

46 (35, 57)